Imaging tumour hypoxia with Positron Emission Tomography

I N Fleming, R Manavaki, P J Blower, C West, K J Williams, A L Harris, J Domarkas, S Lord, C Baldry, F J Gilbert

Research output: Contribution to journalLiterature review

111 Citations (Scopus)
6 Downloads (Pure)

Abstract

Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its association with an aggressive tumour phenotype and therapeutic resistance. Given its prominent role in oncology, accurate detection of hypoxia is important, as it impacts on prognosis and could influence treatment planning. A variety of approaches have been explored over the years for detecting and monitoring changes in hypoxia in tumours, including biological markers and noninvasive imaging techniques. Positron emission tomography (PET) is the preferred method for imaging tumour hypoxia due to its high specificity and sensitivity to probe physiological processes in vivo, as well as the ability to provide information about intracellular oxygenation levels. This review provides an overview of imaging hypoxia with PET, with an emphasis on the advantages and limitations of the currently available hypoxia radiotracers.
Original languageEnglish
Pages (from-to)238-250
Number of pages13
JournalBritish Journal of Cancer
Volume112
Issue number2
Early online date16 Dec 2014
DOIs
Publication statusPublished - 20 Jan 2015

Fingerprint

Positron-Emission Tomography
Physiological Phenomena
Tumor Biomarkers
Neoplasms
Tumor Hypoxia
Hypoxia
Phenotype
Sensitivity and Specificity
Therapeutics

Keywords

  • positron emission tomography (PET)
  • imaging
  • oncology
  • cancer
  • hypoxia
  • radiotracer

Cite this

Fleming, I. N., Manavaki, R., Blower, P. J., West, C., Williams, K. J., Harris, A. L., ... Gilbert, F. J. (2015). Imaging tumour hypoxia with Positron Emission Tomography. British Journal of Cancer, 112(2), 238-250. https://doi.org/10.1038/bjc.2014.610

Imaging tumour hypoxia with Positron Emission Tomography. / Fleming, I N; Manavaki, R; Blower, P J; West, C; Williams, K J ; Harris, A L; Domarkas, J; Lord, S; Baldry, C; Gilbert, F J.

In: British Journal of Cancer, Vol. 112, No. 2, 20.01.2015, p. 238-250.

Research output: Contribution to journalLiterature review

Fleming, IN, Manavaki, R, Blower, PJ, West, C, Williams, KJ, Harris, AL, Domarkas, J, Lord, S, Baldry, C & Gilbert, FJ 2015, 'Imaging tumour hypoxia with Positron Emission Tomography', British Journal of Cancer, vol. 112, no. 2, pp. 238-250. https://doi.org/10.1038/bjc.2014.610
Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL et al. Imaging tumour hypoxia with Positron Emission Tomography. British Journal of Cancer. 2015 Jan 20;112(2):238-250. https://doi.org/10.1038/bjc.2014.610
Fleming, I N ; Manavaki, R ; Blower, P J ; West, C ; Williams, K J ; Harris, A L ; Domarkas, J ; Lord, S ; Baldry, C ; Gilbert, F J. / Imaging tumour hypoxia with Positron Emission Tomography. In: British Journal of Cancer. 2015 ; Vol. 112, No. 2. pp. 238-250.
@article{ec12e8be25ec40748a27fc24e8ce1adc,
title = "Imaging tumour hypoxia with Positron Emission Tomography",
abstract = "Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its association with an aggressive tumour phenotype and therapeutic resistance. Given its prominent role in oncology, accurate detection of hypoxia is important, as it impacts on prognosis and could influence treatment planning. A variety of approaches have been explored over the years for detecting and monitoring changes in hypoxia in tumours, including biological markers and noninvasive imaging techniques. Positron emission tomography (PET) is the preferred method for imaging tumour hypoxia due to its high specificity and sensitivity to probe physiological processes in vivo, as well as the ability to provide information about intracellular oxygenation levels. This review provides an overview of imaging hypoxia with PET, with an emphasis on the advantages and limitations of the currently available hypoxia radiotracers.",
keywords = "positron emission tomography (PET), imaging, oncology, cancer, hypoxia, radiotracer",
author = "Fleming, {I N} and R Manavaki and Blower, {P J} and C West and Williams, {K J} and Harris, {A L} and J Domarkas and S Lord and C Baldry and Gilbert, {F J}",
note = "ACKNOWLEDGEMENTS Cancer Research UK (CRUK) funded the National Cancer Research Institute (NCRI) PET Research Working party to organise a meeting to discuss imaging cancer with hypoxia tracers and Positron Emission Tomography. IF was funded by CRUK and is also supported by the Chief Scientific Office. ALH is supported by CRUK and the Breast Cancer Research Foundation. RM is funded by NIHR Cambridge Biomedical Research Centre. We would also like to thank Professors Tim Eisen and Duncan Jodrell, University of Cambridge, UK and Dr Anastasia Chalkidou, King’s College London, UK for providing the 18F-FMISO and 64CuATSM images illustrated in this review",
year = "2015",
month = "1",
day = "20",
doi = "10.1038/bjc.2014.610",
language = "English",
volume = "112",
pages = "238--250",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Imaging tumour hypoxia with Positron Emission Tomography

AU - Fleming, I N

AU - Manavaki, R

AU - Blower, P J

AU - West, C

AU - Williams, K J

AU - Harris, A L

AU - Domarkas, J

AU - Lord, S

AU - Baldry, C

AU - Gilbert, F J

N1 - ACKNOWLEDGEMENTS Cancer Research UK (CRUK) funded the National Cancer Research Institute (NCRI) PET Research Working party to organise a meeting to discuss imaging cancer with hypoxia tracers and Positron Emission Tomography. IF was funded by CRUK and is also supported by the Chief Scientific Office. ALH is supported by CRUK and the Breast Cancer Research Foundation. RM is funded by NIHR Cambridge Biomedical Research Centre. We would also like to thank Professors Tim Eisen and Duncan Jodrell, University of Cambridge, UK and Dr Anastasia Chalkidou, King’s College London, UK for providing the 18F-FMISO and 64CuATSM images illustrated in this review

PY - 2015/1/20

Y1 - 2015/1/20

N2 - Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its association with an aggressive tumour phenotype and therapeutic resistance. Given its prominent role in oncology, accurate detection of hypoxia is important, as it impacts on prognosis and could influence treatment planning. A variety of approaches have been explored over the years for detecting and monitoring changes in hypoxia in tumours, including biological markers and noninvasive imaging techniques. Positron emission tomography (PET) is the preferred method for imaging tumour hypoxia due to its high specificity and sensitivity to probe physiological processes in vivo, as well as the ability to provide information about intracellular oxygenation levels. This review provides an overview of imaging hypoxia with PET, with an emphasis on the advantages and limitations of the currently available hypoxia radiotracers.

AB - Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its association with an aggressive tumour phenotype and therapeutic resistance. Given its prominent role in oncology, accurate detection of hypoxia is important, as it impacts on prognosis and could influence treatment planning. A variety of approaches have been explored over the years for detecting and monitoring changes in hypoxia in tumours, including biological markers and noninvasive imaging techniques. Positron emission tomography (PET) is the preferred method for imaging tumour hypoxia due to its high specificity and sensitivity to probe physiological processes in vivo, as well as the ability to provide information about intracellular oxygenation levels. This review provides an overview of imaging hypoxia with PET, with an emphasis on the advantages and limitations of the currently available hypoxia radiotracers.

KW - positron emission tomography (PET)

KW - imaging

KW - oncology

KW - cancer

KW - hypoxia

KW - radiotracer

U2 - 10.1038/bjc.2014.610

DO - 10.1038/bjc.2014.610

M3 - Literature review

VL - 112

SP - 238

EP - 250

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -